GPP
CYTK icon

Great Point Partners’s Cytokinetics CYTK Stock Holding History

Great Point Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$8.24M – 35
2025
Q3 		$8.24M Hold
150,000
– – 3.4% 10
2025
Q2 		$4.96M Sell
150,000
-220,000
-59% -$7.65M 3.22% 13
2025
Q1 		$14.9M Buy
370,000
+10,000
+3% +$460K 7.88% 1
2024
Q4 		$16.9M Buy
360,000
+44,000
+14% +$2.29M 7.98% 2
2024
Q3 		$16.7M Sell
316,000
-158,202
-33% -$8.82M 4.91% 6
2024
Q2 		$25.7M Buy
474,202
+272,000
+135% +$16.4M 4.92% 9
2024
Q1 		$14.2M Sell
202,202
-297,798
-60% -$23M 2.21% 21
2023
Q4 		$41.7M Sell
500,000
-100,000
-17% -$3.62M 7.11% 2
2023
Q3 		$17.7M Hold
600,000
– – 3.22% 12
2023
Q2 		$19.6M Buy
600,000
+100,000
+20% +$3.7M 3.83% 11
2023
Q1 		$17.6M Buy
+500,000
New +$20.4M 3.45% 12
2022
Q3 		– Sell
-610,000
Closed -$24M – 43
2022
Q2 		$24M Sell
610,000
-40,000
-6% -$1.61M 5.75% 3
2022
Q1 		$23.9M Buy
650,000
+300,000
+86% +$10.7M 5.78% 6
2021
Q4 		$16M Sell
350,000
-41,429
-11% -$1.6M 3.54% 11
2021
Q3 		$14M Buy
+391,429
New +$11.5M 3.26% 12
2020
Q4 		– Sell
-2,549,525
Closed -$55.2M – 36
2020
Q3 		$55.2M Buy
2,549,525
+1,028,890
+68% +$24.1M 4.97% 8
2020
Q2 		$35.8M Buy
1,520,635
+856,538
+129% +$16.1M 2.87% 13
2020
Q1 		$7.83M Buy
664,097
+504,024
+315% +$6.43M 0.82% 26
2019
Q4 		$1.7M Buy
+160,073
New +$1.64M 0.15% 35
2019
Q1 		– Sell
-3,173,288
Closed -$20.1M – 43
2018
Q4 		$20.1M Buy
3,173,288
+993,600
+46% +$7.29M 2.53% 17
2018
Q3 		$21.5M Buy
2,179,688
+735,207
+51% +$5.9M 3.35% 16
2018
Q2 		$12M Buy
+1,444,481
New +$12M 1.66% 22
2014
Q2 		– Sell
-315,000
Closed -$2.99M – 40
2014
Q1 		$2.99M Buy
+315,000
New +$2.85M 1.56% 23

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Great Point Partners's CYTK Position: Q4 2025 in Review

Great Point Partners sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 150,000 shares — an estimated $8.24M sold.

Great Point Partners first reported a position in CYTK in Q1 2014 and held it in 23 quarters. The position peaked at $55.2M in Q3 2020. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Great Point Partners reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Great Point Partners sold 150,000 Cytokinetics shares in Q4 2025, an estimated $8.24M.
  • Great Point Partners first reported a position in Cytokinetics in Q1 2014 and held it in 23 quarters.
  • Great Point Partners's Cytokinetics position peaked at $55.2M in Q3 2020.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.